Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Determining Predictors of Safe Discontinuation of Anti-TNF Treatment in JIA

Study:

Improved Understanding of the Biology and Use of TNF Inhibition in Children With JIA

Rationale:

n/a

Purpose:

Polyarticular juvenile idiopathic arthritis (Poly JIA) is a form of juvenile arthritis, which is a chronic disease affecting approximately 250,000 people younger than 16 years of age. Poly JIA can be treated with anti-tumor necrosis factor (anti-TNF), a type of medication that is often effective but also has some toxic side effects and is expensive. Among those with poly JIA who are effectively treated with anti-TNF, some can remain healthy off the medication, but some begin to feel the effects of their disease again once the medication is stopped. This study will attempt to find whether certain tests or signs can predict which people with poly JIA can safely stop their anti-TNF medications.

Study Status: Active, not recruiting

Recruiting:
n/a

Condition Intervention Phase
Juvenile Idiopathic Arthritis Other: Withdrawal of anti-TNF therapy Phase 4

Verified by Children`s Hospital Medical Center, Cincinnati October, 2013

Sponsored by: Children`s Hospital Medical Center, Cincinnati
Information provided by: Children`s Hospital Medical Center, Cincinnati
ClinicalTrials.gov identifier: NCT00792233

Study Type: Interventional

Study Design: Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Daniel J. Lovell, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site